Quantum BioPharma Refutes Law Firm Allegations as Unsubstantiated

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has issued a formal response rejecting what it described as vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company stated that the announcements lack factual detail or context and appear intended to mislead investors and provoke unwarranted concern. Quantum BioPharma said it is reviewing the conduct of both firms and their principals and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation.

The company maintains its focus on developing innovative treatments for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is advancing its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, making this research particularly significant for patients suffering from this debilitating condition.

Quantum BioPharma's business strategy includes maintaining strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. The company also retains significant interest in Unbuzzd Wellness Inc., holding 20.11% ownership as of March 31, 2025, along with royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once this threshold is reached, the royalty drops to 3% in perpetuity, providing long-term revenue potential.

The company emphasizes that it retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving its ability to leverage its intellectual property across multiple therapeutic applications. This comprehensive approach to drug development and strategic partnerships positions Quantum BioPharma to address multiple market opportunities while maintaining control over its core pharmaceutical assets.

Investors seeking additional information about Quantum BioPharma can access the latest news and updates in the company's newsroom at https://ibn.fm/QNTM. The company's response to the law firm allegations underscores its commitment to transparency and protecting shareholder interests while continuing to advance its pipeline of innovative biopharmaceutical solutions for serious medical conditions.